Research programme: protein phosphatase magnesium-dependent 1 inhibitors - Antisoma/The Institute of Cancer Research
Alternative Names: PPM1D inhibitors - AntisomaLatest Information Update: 15 Jun 2011
At a glance
- Originator Antisoma; The Institute of Cancer Research
- Class
- Mechanism of Action Protein phosphatase 2C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 May 2010 Antisoma is looking for a licensing partnership for the programme
- 07 Oct 2008 Preclinical trials in Cancer in United Kingdom (unspecified route)